Centene completes acquisition of national specialty pharmacy PANTHERx bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
Centene To Acquire PANTHERx Rare Pharmacy For Undisclosed Terms
WASHINGTON (dpa-AFX) - Healthcare company Centene Corp. (CNC) announced Tuesday that it has signed a definitive agreement to acquire PANTHERx Rare Pharmacy, one of the largest and fastest-growing specialty pharmacies in the U.S. specializing in orphan drugs and rare diseases. The terms of the deal were not disclosed.
The transaction is subject to regulatory approvals and is expected to close by the end of 2020.
PANTHERx offers a suite of synchronized compliance, logistics, and analytics solutions to help streamline the process of delivering orphan medications and care to people living with complicated rare diseases.
Centene Signs Definitive Agreement to Acquire PANTHERx Rare Pharmacy (PANTHERx)
News provided by
Share this article
Share this article
ST. LOUIS, Dec. 15, 2020 /PRNewswire/ Centene Corporation (NYSE: CNC) today announced it has signed a definitive agreement to acquire PANTHERx, one of the largest and fastest-growing specialty pharmacies in the United States specializing in orphan drugs and rare diseases. The transaction is subject to regulatory approvals and is expected to close by the end of 2020.
PANTHERx is a leader in rare disease pharmacy, comprehensively serving patients afflicted with rare and devastating conditions through delivery of medicine breakthroughs, clinical excellence, and access solutions. PANTHERx offers a suite of synchronized compliance, logistics, and analytics solutions to help streamline the process of delivering orphan medications and care to people living with complicated rare diseases.